ATAI Stock Summary and Trading Ideas (Atai Beckley N.V - Common Shares | NASDAQ:ATAI)

Atai Beckley NV is a clinical-stage biopharmaceutical company. It aims to develop mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 and BPL-003 for the treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder.

Atai Beckley N.V - Common Shares trades on the NASDAQ stock market under the symbol ATAI.

As of December 17, 2025, ATAI stock price declined to $4.17 with 572,345 million shares trading.

ATAI has a beta of 1.19, meaning it tends to be more sensitive to market movements. ATAI has a correlation of 0.05 to the broad based SPY ETF.

ATAI has a market cap of $1.51 billion. This is considered a Small Cap stock.

Last quarter Atai Beckley N.V - Common Shares reported $749,000 in Revenue and -$.28 earnings per share. This beat revenue expectation by $693,440 and missed earnings estimates by -$.16.

In the last 3 years, ATAI traded as high as $6.75 and as low as $1.03.

The top ETF exchange traded funds that ATAI belongs to (by Net Assets): ARKG, PSIL, AVSC, NUSC, GWX.

ATAI has outperformed the market in the last year with a price return of +213.5% while the SPY ETF gained +12.4%. However, in the short term, ATAI had mixed performance relative to the market. It has underperformed in the last 3 months, returning -10.3% vs +2.5% return in SPY. But in the last 2 weeks, ATAI shares have fared better than the market returning +7.8% compared to SPY -1.0%.

ATAI support price is $4.06 and resistance is $4.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ATAI shares will trade within this expected range on the day.